DPX-Survivac—an investigational vaccine designed to prompt an immune response against cancer cells—will undergo Phase I/II testing in patients with ovarian cancer. This announcement was made by one of the companies involved in developing the vaccine.
Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading cause of cancer death among US women, with roughly 22,000 new cases and 14,000 deaths in 2010. To improve ovarian cancer outcomes, researchers continue to investigate new approaches to the treatment of this disease.
DPX-Survivac is an investigational anticancer vaccine. The vaccine is designed to prompt the body’s immune system to recognize and attack cancer cells. The specific characteristics of ovarian cancer make it a promising target for this vaccine, and initial clinical testing will focus on women with ovarian cancer. The vaccine may also be effective against other types of cancer, and future clinical trials may involve a broader range of cancer types.
The DPX-Survivac clinical trials have not yet begun. Up-to-date information about ongoing clinical trials is available from the National Cancer Institute and eCancerTrials.
Reference: Immunovaccine Media Release. Immunovaccine Inc. announces Phase I/II Clinical Plan for DPX-Survivac to target Ovarian Cancer. November 17, 2010.
Copyright © 2017 CancerConnect. All Rights Reserved.